News >

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

Jason Harris
Published: Tuesday, Mar 13, 2018

Roger-Dansey, MD

Roger-Dansey, MD
The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication